替加环素治疗泛耐药鲍曼不动杆菌感染临床疗效及安全性分析

Clinical efficacy and safety of tigecycline in treatment of extensively drug resistant Acinetobacter baumannii infection

目的:回顾性研究替加环素治疗泛耐药鲍曼不动杆菌(XDRAB)的疗效及安全性。方法:收集2012年6月–2014年1月我院使用替加环素治疗XDRAB感染病例,对其给药方案、联合用药、临床治愈率、细菌清除率及不良反应等数据进行汇总并分析。结果:共收集到13例病例,其中6例为替加环素与其他抗菌药物联合使用;替加环素治疗XDRAB感染临床治愈率为53.8%,细菌清除率为46.2%;有2例患者出现药品不良反应,与替加环素可能相关。结论:替加环素治疗XDRAB感染有良好的临床疗效,在治疗过程中应密切关注其不良反应,权衡收益风险比,为患者提供安全、有效的治疗。

Objective： To retrospectively study the clinical efficacy and safety of tigecycline in treatment of extensively drug resistant Acinetobacter baumannii （XDRAB） infection. Methods： A total of 13 cases of XDRAB infection treated with tigecycline were collected in our hospital from June 2012 to January 2014. Medication regimen, drug combination, clinical efficacy rate, bacteria clearance rate and adverse drug reaction were analyzed respectively. Results： Among the 13 cases, 6 cases were treated by tigecycline combination with other antibacterials. The clinical efficacy rate of tigecycline was 53.8%. Bacteria clearance rate of tigecycline was 46.2%. Two cases showed adverse drug reactions correlated with tigecycline. Conclusion： The tigecycline showed well clinical efficacy on XDRAB infection; meanwhile we should pay close attention to the adverse reactions of tigecycline and balance the benefits and the risks, in order to provide safe and effective treatment for patients.